Article2011

Eszopiclone for the Treatment of Posttraumatic Stress Disorder and Associated Insomnia

Mark H. Pollack · Elizabeth A. Hoge · John J. Worthington · Samantha J. Moshier · Rachel S. Wechsler · Mina Brandes +1 more

101 citations0/0 files storedThe Journal of Clinical Psychiatry

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Abstract

Article Abstract Objective: The development of novel strategies for the treatment of posttraumatic stress disorder (PTSD) represents a critical public health need. We present the first prospective, randomized, double-blind, placebo-controlled trial of a non-benzodiazepine hypnotic agent for the treatment of PTSD and associated insomnia. Method: Twenty-four patients with PTSD by DSM-IV criteria and sleep disturbance were treated in a randomized, double-blind, placebo-controlled crossover study of 3 weeks of eszopiclone 3 mg at bedtime compared to placebo. The primary outcome measures were changes in scores on the Short PTSD Rating Interview (SPRINT) and the Pittsburgh Sleep Quality Index (PSQI). The data were collected from April 2006 to June 2008. Results: Three weeks of eszopiclone pharmacotherapy was associated with significantly greater improvement than placebo on PTSD symptom measures including the SPRINT (P = .032) and the Clinician-Administered PTSD Scale (P = .003), as well as on measures of sleep including the PSQI (P = .011) and sleep latency (P = .044). Greater improvement with eszopiclone on PTSD measures was present even when specific sleep-related items were excluded. Adverse events were consistent with the known profile of the drug. Conclusions: This study provides initial evidence that pharmacotherapy with eszopiclone may be associated with short-term improvement in overall PTSD severity as well as associated sleep disturbance. Longer, more definitive study of eszopiclone in PTSD is warranted. Trial Registration: clinicaltrials.gov Identifier: NCT00120250 J Clin Psychiatry 2011;72(7):892-897 Submitted: August 11, 2009; accepted December 17, 2009. Online ahead of print: February 22, 2010 (doi:10.4088/JCP.09m05607gry). Corresponding author: Mark H. Pollack, MD, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, One Bowdoin Square, Sixth Floor, Boston, MA 02114 (mpollack@partners.org).

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 101 citations exist upstream.

Cited by

2021Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches 2015Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians 2026Pharmacotherapy for post traumatic stress disorder (PTSD)2015Psychopharmacological Strategies in the Management of Posttraumatic Stress Disorder (PTSD): What Have We Learned?2016Pharmacological Treatment of Insomnia 2015Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature 2018Eszopiclone for insomnia

Imported from OpenAlex (CC0) — nothing here is generated.